Clinical Trials · NCT04238962
A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 111
- Start date
- Feb 2020
- Locations
- 1 site, Germany
- Primary endpoint
- AUC0-last,sema,2mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after one dose of s.c. semaglutide 2 mg administration following a 6-week dose escalation period